Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Total Non-Current Liabilities (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $41.5 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 84.11% to $41.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.5 million through Dec 2025, up 84.11% year-over-year, with the annual reading at $41.5 million for FY2025, 84.11% up from the prior year.
  • Total Non-Current Liabilities hit $41.5 million in Q4 2025 for Rapid Micro Biosystems, up from $39.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $135.5 million in Q1 2021 to a low of $18.4 million in Q3 2021.
  • Historically, Total Non-Current Liabilities has averaged $30.2 million across 5 years, with a median of $22.2 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 83.58% in 2022 and later soared 87.51% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $19.0 million in 2021, then skyrocketed by 38.32% to $26.3 million in 2022, then dropped by 4.01% to $25.2 million in 2023, then decreased by 10.64% to $22.5 million in 2024, then surged by 84.11% to $41.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for RPID at $41.5 million in Q4 2025, $39.7 million in Q3 2025, and $20.7 million in Q2 2025.